Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2462209 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2460843 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL203904 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL29418355 | 1.00 | CCR2 (0.60) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2329779 | 0.95 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL4704983 | 0.95 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL2462379 | 0.95 | CCR2 (0.67) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL7327118 | 0.93 | CCR2 (0.57) | CCR2GAACCR1CCR5CXCR4 | |
| SCHEMBL7327122 | 0.93 | CCR2 (0.57) | CCR2GAACCR1CCR5CXCR4 | |
| Acetic Acid SCHEMBL8778037 | 0.92 | CCR2 (0.62) | CCR2GAACCR1CCR5CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| CN-110996950-B | Piperidinone formyl peptide 2 receptor agonists and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-1156803-A4 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-0946589-B1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1156803-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6184207-B1 | A PEPTIDE INCLUDING SPECIFIED PIPERIDINE-CONTAINING GROUP, HAVING AN N-TERMINAL HYDROPHOBIC RESIDUE AND OPTIONALLY AN AMIDATED C-TERMINAL OF SPECIFIED END GROUPS; TREATING MULTIPLE SCLEROSIS OR RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2001-02-06 | — | — | US | disclosed |
| WO-2000047207-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-0946589-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| EP-0789571-A4 | CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE | MERCK & CO INC (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1998025951-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
| EP-0789571-A1 | CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE | Merck & Co., Inc. (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014844-A1 | CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE | MERCK & CO., INC. (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | CCR2 2040/4885GAA 634/4885CCR1 2110/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | CCR2 648/4885GAA 1395/4885CCR1 940/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | CCR2 648/4885GAA 1395/4885CCR1 940/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | CCR2 648/4885GAA 1395/4885CCR1 940/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | CCR2 648/4885GAA 1395/4885CCR1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.